NCT07162571View on ClinicalTrials.gov

This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 1, 2026

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2031

Conditions
Acute Lymphobkastic LeukemiaB Cell Lymphoma
Interventions
BIOLOGICAL

CD19/22 CAR-T cells

Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with doses from 50 x 10⁶ to 150 x 10⁶ CD19/CD22 CAR-T cells

Trial Locations (1)

220087

State Institution Minsk Scientific and Practical Center for Surgery, Transplantology, and Dermatology, Minsk

All Listed Sponsors
lead

Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology

OTHER_GOV

NCT07162571 - This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma. | Biotech Hunter | Biotech Hunter